Tags

Type your tag names separated by a space and hit enter

Intravitreal triamcinolone acetonide in exudative age-related macular degeneration.

Abstract

PURPOSE

To examine the effects of intravitreal injection of 4.0 mg triamcinolone acetonide on the visual and clinical course of exudative age-related macular degeneration.

METHODS

A randomized clinical trial of a single injection of triamcinolone acetonide into the vitreous cavity of experimental eyes at baseline versus observation of untreated subjects was performed in 27 patients followed up for 6 months. Inclusion criteria included exudative age-related macular degeneration with subfoveal or occult choroidal neovascularization, and visual acuity between 20/40 and 20/400. Examination, acuity assessment, fundus photography, and fluorescein angiography were performed at baseline and at 3 and 6 months after enrollment. LogMAR visual acuity was compared between groups by a repeated measures analysis of variance model. Masked assessment of photographic studies was performed and groups were compared with Fisher's exact test.

RESULTS

Visual acuity was significantly better in the treated group compared with control subjects at 3 and 6 months (P < 0.005). Fundus photography and angiography were more likely to show stability or improvement at 3 and 6 months in the treated group (P = 0.05). Intraocular pressure elevation was seen in 25% of treated patients, but was controlled with topical medications. Progression of cataract was more frequently seen in the treated group.

CONCLUSIONS

Intravitreal triamcinolone acetonide may provide short-term improvement in visual acuity and fundus findings in exudative macular degeneration. These findings must be considered preliminary and should be followed by multicenter, masked, placebo-controlled trials with long-term follow-up.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, USA.

    , ,

    Source

    Retina (Philadelphia, Pa.) 20:3 2000 pg 244-50

    MeSH

    Aged
    Aged, 80 and over
    Anti-Inflammatory Agents
    Choroidal Neovascularization
    Female
    Fluorescein Angiography
    Humans
    Injections
    Intraocular Pressure
    Macular Degeneration
    Male
    Middle Aged
    Pilot Projects
    Triamcinolone Acetonide
    Visual Acuity
    Vitreous Body

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    10872928

    Citation

    Danis, R P., et al. "Intravitreal Triamcinolone Acetonide in Exudative Age-related Macular Degeneration." Retina (Philadelphia, Pa.), vol. 20, no. 3, 2000, pp. 244-50.
    Danis RP, Ciulla TA, Pratt LM, et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina (Philadelphia, Pa). 2000;20(3):244-50.
    Danis, R. P., Ciulla, T. A., Pratt, L. M., & Anliker, W. (2000). Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina (Philadelphia, Pa.), 20(3), pp. 244-50.
    Danis RP, et al. Intravitreal Triamcinolone Acetonide in Exudative Age-related Macular Degeneration. Retina (Philadelphia, Pa). 2000;20(3):244-50. PubMed PMID: 10872928.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. AU - Danis,R P, AU - Ciulla,T A, AU - Pratt,L M, AU - Anliker,W, PY - 2000/6/29/pubmed PY - 2000/9/30/medline PY - 2000/6/29/entrez SP - 244 EP - 50 JF - Retina (Philadelphia, Pa.) JO - Retina (Philadelphia, Pa.) VL - 20 IS - 3 N2 - PURPOSE: To examine the effects of intravitreal injection of 4.0 mg triamcinolone acetonide on the visual and clinical course of exudative age-related macular degeneration. METHODS: A randomized clinical trial of a single injection of triamcinolone acetonide into the vitreous cavity of experimental eyes at baseline versus observation of untreated subjects was performed in 27 patients followed up for 6 months. Inclusion criteria included exudative age-related macular degeneration with subfoveal or occult choroidal neovascularization, and visual acuity between 20/40 and 20/400. Examination, acuity assessment, fundus photography, and fluorescein angiography were performed at baseline and at 3 and 6 months after enrollment. LogMAR visual acuity was compared between groups by a repeated measures analysis of variance model. Masked assessment of photographic studies was performed and groups were compared with Fisher's exact test. RESULTS: Visual acuity was significantly better in the treated group compared with control subjects at 3 and 6 months (P < 0.005). Fundus photography and angiography were more likely to show stability or improvement at 3 and 6 months in the treated group (P = 0.05). Intraocular pressure elevation was seen in 25% of treated patients, but was controlled with topical medications. Progression of cataract was more frequently seen in the treated group. CONCLUSIONS: Intravitreal triamcinolone acetonide may provide short-term improvement in visual acuity and fundus findings in exudative macular degeneration. These findings must be considered preliminary and should be followed by multicenter, masked, placebo-controlled trials with long-term follow-up. SN - 0275-004X UR - https://www.unboundmedicine.com/medline/citation/10872928/Intravitreal_triamcinolone_acetonide_in_exudative_age_related_macular_degeneration_ L2 - http://Insights.ovid.com/pubmed?pmid=10872928 DB - PRIME DP - Unbound Medicine ER -